SCHEMBL7129140

SCHEMBL7129140

N#Cc1ccc(Oc2ccccc2)c(N)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
GAA P10253 2/20 0.49
AR P10275 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
CYP2D6 P10635 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CHEK2 O96017 1/20 0.42
CYP19A1 P11511 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31090835 1.00 CYP1A2 (0.57) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
Hydrochloric Acid SCHEMBL7010096 0.84 MAOB (0.61) CYP1A2CYP2C9CYP2C19CYP3A4GAA
SCHEMBL810984 0.83 AR (0.48) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL30515469 0.81 AR (0.58) ALDH1A1KDM4EGAAARSMN1; SMN2
SCHEMBL3421698 0.81 AR (0.58) ALDH1A1KDM4EGAAARSMN1; SMN2
SCHEMBL2033412 0.80 EPAS1 (0.44) AR
SCHEMBL692939 0.80 AR (0.51) ALDH1A1GAAARSMN1; SMN2SLC6A4
SCHEMBL2819246 0.80 MAPT (0.47) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL7020181 0.79 AR (0.46) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL7486665 0.79 TTR (0.56) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114448-A1 Inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-06-19 US disclosed
WO-2002096873-A1 ISOINDOLE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF FACTOR XA MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-12-05 WO disclosed
US-5547966-A Aryl urea and related compounds BRISTOL-MYERS SQUIBB COMPANY (US) 1996-08-20 US disclosed
EP-0656350-A1 Biaryl urea and related compounds BRISTOL-MYERS SQUIBB COMPANY (US) 1995-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114448-A1 Inhibitors of factor Xa SERPINC1, F11, TFPI CYP1A2 2682/4885CYP2C9 1457/4885CYP2C19 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.